<DOC>
	<DOCNO>NCT00161642</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability maximum tolerate dose CMD-193 . Preliminary information person 's body process CMD-193 CMD-193 affect tumor also collect .</brief_summary>
	<brief_title>Study Evaluating CMD-193 Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically confirm malignant solid tumor progress follow standard therapy , standard effective treatment available Tumor expression Lewis Y antigen ( &gt; = 20 % tumor cell positive Lewis Y immunohistochemistry assay ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Chemotherapy , radiation therapy , cancer therapy , investigational agent within 21 day first dose CMD193 ( 42 day previous chemotherapy include nitrosoureas mitomycin C ) Symptomatic clinically active CNS metastasis . Subjects prior treatment radiotherapy surgical resection CNS metastases permit CNS metastasis remain stable require treatment least 3 month prior first dose CMD193 . Significant prior allergic reaction recombinant human murine protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Malignant Tumors</keyword>
</DOC>